[1]刘艳,刘少稳.新型口服抗凝药物在老年非瓣膜性心房颤动
患者抗凝治疗中的作用[J].国际心血管病杂志,2023,01:24-28.
点击复制
新型口服抗凝药物在老年非瓣膜性心房颤动
患者抗凝治疗中的作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年01期
- 页码:
- 24-28
- 栏目:
- 综述
- 出版日期:
- 2023-01-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.01.007
- 文献标识码:
- -
- 摘要:
- 心房颤动（房颤）是临床上常见的快速性心律失常，是卒中和栓塞的独立危险 因素。大多数非瓣膜性房颤患者超过65 岁，对老年房颤患者行抗凝治疗可有效预防血栓栓 塞事件，降低患者的致残率和致死率。目前指南推荐老年房颤患者使用新型口服抗凝药，该 文介绍老年房颤患者抗凝治疗选择。
- Abstract:
- -
参考文献/References
[1] Du X, Guo LZ, Xia SJ, et al. Atrial fibrillation prevalence,
awareness and management in a nationwide survey of adults
in China[J]. Heart, 2021, 107(7):535-541.
[2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major
contributor to stroke in the elderly. The Framingham Study[J].
Arch Intern Med, 1987, 147(9):1561-1564.
[3] Cowan JC, Wu JH, Hall M, et al. A 10 year study of
hospitalized atrial fibrillation-related stroke in England and its
association with uptake of oral anticoagulation[J]. Eur Heart J,
2018, 39(32):2975-2983.
[4] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines
for the management of atrial fibrillation developed in
collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-
2962.
[5] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the
efficacy and safety of new oral anticoagulants with warfarin in
patients with atrial fibrillation: a meta-analysis of randomised
trials[J]. Lancet, 2014, 383(9921):955-962.
[6] Wei Y, Xu J, Wu HQ, et al. Survey of antithrombotic treatment
in rural patients (>60 years) with atrial fibrillation in east
China[J]. Sci Rep, 2018, 8(1):6830.
[7] Guo YT, Kotalczyk A, Imberti JF, et al. Poor adherence
to guideline-directed anticoagulation in elderly Chinese
patients with atrial fibrillation. A report from the Optimal
Thromboprophylaxis in Elderly Chinese Patients with Atrial
Fibrillation (ChiOTEAF) registry[J]. Eur Heart J Qual Care
Clin Outcomes, 2021:qcab054.
[8] Guo YT, Kotalczyk A, Imberti JF, et al. Poor adherence
to guideline-directed anticoagulation in elderly Chinese
patients with atrial fibrillation. A report from the Optimal
Thromboprophylaxis in Elderly Chinese Patients with Atrial
Fibrillation (ChiOTEAF) registry[J]. Int J Stroke, 2022,
17(6):661-668.
[9] Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk
stratification schemes for ischaemic stroke and bleeding in
182 678 patients with atrial fibrillation: the Swedish Atrial
fibrillation cohort study[J]. Eur Heart J, 2012, 33(12):1500-
1510.
[10] Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme
to predict ischemic stroke and other thromboembolism in atrial
fibrillation: the ATRIA study stroke risk score[J]. J Am Heart
Assoc, 2013, 2(3):e000250.
[11] Wang XJ, Fu Q, Song FJ, et al. Prevalence of atrial fibrillation
in different socioeconomic regions of China and its association
with stroke: results from a National stroke screening survey[J].
Int J Cardiol, 2018, 271:92-97.
[12] Bassand JP, Virdone S, Goldhaber SZ, et al. Early risks of
death, stroke/systemic embolism, and major bleeding in
patients with newly diagnosed atrial fibrillation[J]. Circulation,
2019, 139(6):787-798.
[13] Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk,
bleeding outcomes and effect of different antithrombotic
strategies in very elderly patients with atrial fibrillation:
a sub-analysis from the PREFER in AF (PREvention
oF thromboembolic events- European Registry in a trial
Fibrillation)[J]. J Am Heart Assoc, 2017, 6(7):e005657.
[14] Singer DE, Chang Y, Fang MC, et al. The net clinical benefit
of warfarin anticoagulation in atrial fibrillation[J]. Ann Intern
Med, 2009, 151(5):297-305.
[15] Bando S, Nishikado A, Hiura N, et al. Efficacy and safety of
rivaroxaban in extreme elderly patients with atrial fibrillation:
analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)[J].
J Cardiol, 2018, 71(2):197-201.
[16] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines
for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association
for Cardio-Thoracic Surgery (EACTS): the task force for the
diagnosis and management of atrial fibrillation of the European
Society of Cardiology (ESC) developed with the special
contribution of the European Heart Rhythm Association
(EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
[17] Kim IS, Kim HJ, Kim TH, et al. Non-vitamin K antagonist
oral anticoagulants have better efficacy and equivalent safety
compared to warfarin in elderly patients with atrial fibrillation:
a systematic review and meta-analysis[J]. J Cardiol, 2018,
72(2):105-112.
[18] Chao TF, Chiang CE, Liao JN, et al. Comparing the
effectiveness and safety of nonvitamin K antagonist oral
anticoagulants and warfarin in elderly Asian patients with
atrial fibrillation: a nationwide cohort study[J]. Chest, 2020,
157(5):1266-1277.
[19] Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very
elderly patients with atrial fibrillation: a nationwide cohort
study[J]. Circulation, 2018, 138(1):37-47.
[20] Fehrman-Ekholm I, Skeppholm L. Renal function in the
elderly (>70 years old) measured by means of iohexol
clearance, serum creatinine, serum urea and estimated
clearance[J]. Scand J Urol Nephrol, 2004, 38(1):73-77.
[21] Posch F, Ay C, St?ger H, et al. Exposure to vitamin k
antagonists and kidney function decline in patients with
atrial fibrillation and chronic kidney disease[J]. Res
PractThrombHaemost, 2019, 3(2):207-216.
[22] Chan KE, Lazarus JM, Thadhani R, et al. Anticoagulant and
antiplatelet usage associates with mortality among hemodialysis
patients[J]. J Am Soc Nephrol, 2009, 20(4):872-881.
[23] Brodsky SV, Collins M, Park E, et al. Warfarin therapy that
results in an international normalization ratio above the
therapeutic range is associated with accelerated progression
of chronic kidney disease[J]. Nephron Clin Pract, 2010,
115(2):c142-c146.
[24] Yao AA, Tangri N, Gersh BJ, et al. Renal outcomes in
anticoagulated patients with atrial fibrillation[J]. J Am Coll
Cardiol, 2017, 70(21):2621-2632.
[25] Pokorney SD, Black-Maier E, Hellkamp AS, et al. Oral
anticoagulation and cardiovascular outcomes in patients with
atrial fibrillation and end-stage renal disease[J]. J Am Coll
Cardiol, 2020, 75(11):1299-1308.
[26] Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of
bleeding with 2 doses of dabigatran compared with warfarin in
older and younger patients with atrial fibrillation: an analysis
of the randomized evaluation of long-term anticoagulant
therapy (RE-LY) trial[J]. Circulation, 2011, 123(21):2363-
2372.
[27] Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding,
and mortality risks of dabigatran in asians with nonvalvular
atrial fibrillation[J]. Stroke, 2016, 47(2):441-449.
[28] Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and
safety of rivaroxaban compared with warfarin among elderly
patients with nonvalvular atrial fibrillation in the rivaroxaban
once daily, oral, direct factor Xainhibition compared with
vitamin K antagonism for prevention of stroke and embolism
trial in atrial fibrillation (ROCKET AF)[J]. Circulation, 2014,
130(2):138-146.
[29] Hanon O, Vidal JS, Pisica-Donose G, et al. Bleeding risk with
rivaroxaban compared with vitamin K antagonists in patients
aged 80 years or older with atrial fibrillation[J]. Heart, 2021,
107(17):1376-1382.
[30] Granger CB, Alexander JH, McMurray JJV, et al. Apixaban
versus warfarin in patients with atrial fibrillation[J]. N Engl J
Med, 2011, 365(11):981-992.
[31] Halvorsen S, Atar D, Yang HQ, et al. Efficacy and safety of
apixaban compared with warfarin according to age for stroke
prevention in atrial fibrillation: observations from the Aristotle
trial[J]. Eur Heart J, 2014, 35(28):1864-1872.
[32] Sch?fer A, Flierl U, Berliner D, et al. Anticoagulants for
stroke prevention in atrial fibrillation in elderly patients[J].
Cardiovasc Drugs Ther, 2020, 34(4):555-568.
[33] Shah SJ, Singer DE, Fang MC, et al. Net clinical benefit of oral
anticoagulation among older adults with atrial fibrillation[J].
Circ Cardiovasc Qual Outcomes, 2019, 12(11):e006212.
[34] Lip GYH, Keshishian A, Li XY, et al. Effectiveness and safety
of oral anticoagulants among nonvalvular atrial fibrillation
patients[J]. Stroke, 2018, 49(12):2933-2944.
[35] Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and
safety of non-vitamin K oral anticoagulants in comparison
to phenprocoumon: data from 61,000 patients with atrial
fibrillation[J]. ThrombHaemost, 2018, 118(3):526-538.
[36] Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety
of edoxaban in elderly patients with atrial fibrillation in the
ENGAGE AF-TIMI 48 trial[J]. J Am Heart Assoc, 2016,
5(5):e003432.
[37] Okumura K, Akao MSH, Yoshida T, et al. Low-dose edoxaban
in very elderly patients with atrial fibrillation[J]. N Engl J
Med, 2020, 383(18):1735-1745.
[38] Heidbuchel H, Verhamme P, Alings M, et al. Updated
European Heart Rhythm Association practical guide on the use
of non-vitamin-K antagonist anticoagulants in patients with
non-valvular atrial fibrillation: executive summary[J]. Eur
Heart J, 2017, 38(27):2137-2149.
[39] Kim D, Yang PS, Jang E, et al. Association of anticoagulant
therapy with risk of dementia among patients with atrial
fibrillation[J]. Europace, 2021, 23(2):184-195.
备注/Memo
- 备注/Memo:
-
基金项目：上海申康医院发展中心临床三年行动计划项目
（SHDC2020CR6012）
通信作者：刘少稳，Email：shaowen.liu@hotmail.com
常用功能
统计/Statistics
- 摘要浏览/Viewed103
- 全文下载/Downloads248
- 评论/Comments
